Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C

Background: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. Aim: To report our experience in the t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pizarro,Carolina, Venegas,Mauricio, Hola,Karen, Smok,Gladys, Brahm,Javier
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Hepatitis C chronic hepatitis C virus peginterferon alfa-za
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000600002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011000600002
record_format	dspace
spelling	oai:scielo:S0034-988720110006000022011-09-14Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica CPizarro,CarolinaVenegas,MauricioHola,KarenSmok,GladysBrahm,Javier Hepatitis C chronic hepatitis C virus peginterferon alfa-za Background: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. Aim: To report our experience in the treatment of chronic hepatitis C. Material and Methods: Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day. Results: Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4% of patients, respectively. Twenty four patients (46 %), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment. Conclusions: Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.6 20112011-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000600002es10.4067/S0034-98872011000600002
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hepatitis C chronic hepatitis C virus peginterferon alfa-za
spellingShingle	Hepatitis C chronic hepatitis C virus peginterferon alfa-za Pizarro,Carolina Venegas,Mauricio Hola,Karen Smok,Gladys Brahm,Javier Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
description	Background: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. Aim: To report our experience in the treatment of chronic hepatitis C. Material and Methods: Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day. Results: Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4% of patients, respectively. Twenty four patients (46 %), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment. Conclusions: Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.
author	Pizarro,Carolina Venegas,Mauricio Hola,Karen Smok,Gladys Brahm,Javier
author_facet	Pizarro,Carolina Venegas,Mauricio Hola,Karen Smok,Gladys Brahm,Javier
author_sort	Pizarro,Carolina
title	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
title_short	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
title_full	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
title_fullStr	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
title_full_unstemmed	Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
title_sort	resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica c
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000600002
work_keys_str_mv	AT pizarrocarolina resultadosdeltratamientoconpeginterferonalfa2ayribavirinaenpacientesconhepatitiscronicac AT venegasmauricio resultadosdeltratamientoconpeginterferonalfa2ayribavirinaenpacientesconhepatitiscronicac AT holakaren resultadosdeltratamientoconpeginterferonalfa2ayribavirinaenpacientesconhepatitiscronicac AT smokgladys resultadosdeltratamientoconpeginterferonalfa2ayribavirinaenpacientesconhepatitiscronicac AT brahmjavier resultadosdeltratamientoconpeginterferonalfa2ayribavirinaenpacientesconhepatitiscronicac
_version_	1718436569653706752

Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C

Ejemplares similares